Drugs / Tirzepatide
Tirzepatide
Regulatory milestones approvals, filings & regulatory actions · 13 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed obesity disorder 4 milestones | |||||
| Filed | US (FDA) | — | obesity disorder | 2023-06-24 | “With these results in hand, we have completed our submission for chronic weight management to the U.S. FDA.” lilly.com ↗ |
| Filed | EU (EMA) | — | obesity disorder | 2023-04-27 | “regulatory submissions of tirzepatide for obesity in the EU” lilly.com ↗ |
| Filed | US (FDA) | — | obesity disorder | 2023-02-02 | “initiated a rolling submission in the U.S. for tirzepatide in obesity” lilly.com ↗ |
| Filed | Japan (PMDA) | — | obesity disorder | — | “announced that Eli Lilly Japan had applied for approval of tirzepatide (hereinafter referred to as "the product") from the Ministry of Health, Labour and Welfare” tanabe-pharma.com ↗ |
| Filed obstructive sleep apnea syndrome 2 milestones | |||||
| Filed | EU (EMA) | — | obstructive sleep apnea syndrome | 2024-11-16 | “Lilly submitted tirzepatide for the treatment of HFpEF and obesity to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)” lilly.com ↗ “Submission of tirzepatide in the U.S. and EU for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity” lilly.com ↗ |
| Filed | US (FDA) | — | obstructive sleep apnea syndrome | 2024-06-21 | “Submission of tirzepatide in the U.S. and EU for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity” lilly.com ↗ “Lilly submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA)” lilly.com ↗ |
| Approved Indication not stated 6 milestones | |||||
| Filed | US (FDA) | — | — | 2026-08-06 | “the U.S. Food and Drug Administration (FDA) has accepted for review two Abbreviated New Drug Applications (ANDAs) for generic tirzepatide injection in the United States” gedeonrichter.com ↗ |
| Label expansion | US (FDA) | MOUNJARO | — | 2025-12-19 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ZEPBOUND | — | 2024-10-18 – 2024-12-20 | fda.gov ↗ |
| Filed | US (FDA) | — | heart failure with preserved ejection fraction, obesity | 2024-11-16 | “Lilly submitted tirzepatide for the treatment of HFpEF and obesity to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)” lilly.com ↗ |
| Approved | EU (EMA) | Mounjaro | — | 2022-09-15 | europa.eu ↗ |
| Approved | US (FDA) | MOUNJARO | — | 2022-05-13 | fda.gov ↗ |
Trials 170 · started per year
today
US approved 2022
EU approved 2022
1
4
2
13
9
6
6
15
23
40
48
3
201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT07812636 | Nov 2026 → May 2028 expected | atypical endometrial hyperplasia, endometrial endometrioid adenocarcinoma, metabolic disease | Milton S. Hershey Medical Center | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07065552 | Apr 2026 → Jul 2028 expected | endometrial cancer, obesity disorder | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06759701 | Jul 2025 → Dec 2026 expected | diabetes mellitus, prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06934642 | Jun 2025 → Oct 2026 expected | metabolic dysfunction-associated steatotic liver disease, obesity disorder | University of New Mexico | Recruiting | No outcome recorded |
| Phase 0 | NCT06734273 | Mar 2025 → Sep 2027 expected | obesity disorder | Nicholas Skertich | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06751589 | Dec 2024 → Dec 2027 expected | endometrial cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 127 trials · 2 met primary · 2 missed | ||||||
| Phase 1 | NCT07868354 | Oct 2026 → Sep 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07803744 | Sep → Dec 2026 expected | obesity disorder, type 1 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07095517 | Feb 2026 → Mar 2027 expected | colorectal adenoma, colorectal cancer | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07299084 | Jan → Nov 2026 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06916065 | Apr 2025 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06890611 | Mar → Sep 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06648031 | Dec 2024 → Jul 2025 | type 2 diabetes mellitus | Lexaria Bioscience Corp. | Completed | No outcome recorded |
| Phase 1 | NCT06575738 | Oct 2024 → Sep 2027 expected | obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06297616 | Apr 2024 → Nov 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05978713 | Jul 2023 → Mar 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05810597 | Apr → Jul 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05696847 | Feb 2023 → Jan 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04235959 | Oct 2020 → Aug 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04407234 | Sep 2020 → Jan 2021 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04311411 | Aug 2020 → Dec 2022 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 1 | NCT04311424 | Jul → Oct 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04081337 | Jul 2020 → May 2022 | obesity disorder | Eli Lilly and Company | Completed | Missed primary |
| Phase 1 | NCT04172987 | Feb 2020 → Feb 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04050553 | Feb 2020 → Jan 2022 | hypoglycemia, type 2 diabetes mellitus | Eli Lilly and Company | Completed | Missed primary |
| Phase 1 | NCT04050670 | Sep 2019 → Apr 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04004988 | Aug → Dec 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03940742 | Jul 2019 → Sep 2020 | liver disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03951753 | Jun 2019 → Apr 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 1 | NCT03482024 | Mar 2018 → Aug 2019 | end stage renal failure, impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03375463 | Dec 2017 → Dec 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03322631 | Nov 2017 → May 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02759107 | May 2016 → Jun 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07463846 | Mar 2026 → Apr 2027 expected | obesity disorder | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05751720 | Oct 2023 → Oct 2024 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Dr Adnan Agha | Unknown | No outcome recorded |
| Phase 246 trials · 3 met primary | ||||||
| Phase 2 | NCT07265752 | Mar 2027 → Jun 2028 expected | cannabis dependence | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07078838 | Jan 2027 → Mar 2029 expected | endometrial cancer, endometrial endometrioid adenocarcinoma, intraepithelial neoplasia | UNC Lineberger Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06180616 | Dec 2026 → Dec 2028 expected | type 1 diabetes mellitus | Royal North Shore Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07468552 | Nov 2026 → Mar 2028 expected | cannabis dependence | National Institute on Drug Abuse (NIDA) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07825857 | Oct 2026 → Jul 2031 expected | methamphetamine dependence | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07734870 | Sep 2026 → May 2028 expected | central centrifugal cicatricial alopecia | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT07693608 | Aug 2026 → Feb 2030 expected | cocaine dependence, methamphetamine dependence, obesity disorder | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06820281 | Jul 2026 → Dec 2027 expected | type 1 diabetes mellitus | Victor Chang Cardiac Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07349641 | Jul 2026 → Dec 2028 expected | atypical endometrial hyperplasia, endometrial endometrioid adenocarcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07602699 | Jun 2026 → Mar 2028 expected | — | University of Southern California | Recruiting | No outcome recorded |
| Phase 2 | NCT07605247 | Jun 2026 → Jan 2028 expected | endometrial cancer | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527910 | May 2026 → Mar 2030 expected | metabolic dysfunction-associated steatotic liver disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07179120 | May → Aug 2026 overdue | male infertility | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07228741 | Apr 2026 → Nov 2027 expected | childhood acute lymphoblastic leukemia, obesity disorder | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07107334 | Apr 2026 → Nov 2028 expected | endometrial endometrioid adenocarcinoma | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT06811324 | Apr 2026 → Apr 2027 expected | pelvic muscle wasting | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 2 | NCT06651177 | Jan 2026 → Sep 2027 expected | opiate dependence | T. John Winhusen, PhD | Recruiting | No outcome recorded |
| Phase 2 | NCT07202247 | Jan 2026 → Apr 2028 expected | prostate carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07292519 | Jan 2026 → May 2027 expected | alcohol-related disorders, obesity disorder | South West Sydney Local Health District | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06935838 | Nov 2025 → Jun 2026 | HIV infectious disease, obesity disorder | University of Hawaii | Completed | No outcome recorded |
| Phase 2 | NCT05933499 | Nov 2025 → Dec 2028 expected | obesity disorder | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06994338 | Oct 2025 → Aug 2026 overdue | alcohol-related disorders, obesity disorder | University of Southern California | Recruiting | No outcome recorded |
| Phase 2 | NCT06847399 | Sep 2025 → Dec 2027 expected | binge eating disorder, obesity disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT06727331 | Sep 2025 → Mar 2027 expected | alcohol-related disorders | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07091734 | Sep 2025 → Sep 2029 expected | partial lipodystrophy | University of Michigan | Recruiting | No outcome recorded |
| Phase 2 | NCT06901349 | May → Jun 2025 | obesity disorder | Eli Lilly and Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06976853 | May 2025 → May 2028 expected | Crohn disease | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06939088 | May 2025 → Aug 2028 expected | alcohol dependence, schizophrenia | Anders Fink-Jensen, MD, DMSci | Recruiting | No outcome recorded |
| Phase 2 | NCT06802081 | Apr 2025 → Dec 2026 expected | atrial fibrillation, obesity disorder | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06893211 | Mar → Nov 2025 | obesity disorder | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 2 | NCT06582875 | Mar 2025 → Jun 2029 expected | autosomal dominant polycystic kidney disease, obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT06745128 | Feb 2025 → Feb 2026 | methamphetamine dependence, obesity disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT06517212 | Nov 2024 → Aug 2029 expected | breast cancer | Baylor Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06518837 | Oct 2024 → Sep 2027 expected | hormone receptor-positive breast cancer | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT06643728 | Oct 2024 → Jan 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06603571 | Sep 2024 → Jul 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06515418 | Jun 2024 → Feb 2025 | obesity disorder | BioAge Labs, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT06373146 | Apr 2024 → Dec 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05659368 | Jan → Oct 2024 | Wolfram syndrome 1 | Ospedale San Raffaele | Unknown | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05912621 | Nov 2023 → Jun 2028 expected | morbid obesity | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT06037252 | Sep 2023 → Jan 2026 overdue | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05536804 | Feb 2023 → Jul 2026 | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04166773 | Nov 2019 → Dec 2023 | metabolic dysfunction-associated steatohepatitis | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT03311724 | Oct 2017 → Apr 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT03131687 | May 2017 → Aug 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07846865 | Oct 2026 → Dec 2028 expected | obesity disorder, obstructive sleep apnea syndrome | Woolcock Institute of Medical Research | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07734792 | Sep 2026 → May 2028 expected | ischemic stroke | yifang zhu | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07284511 | May 2026 → Jan 2028 expected | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07223242 | Feb 2025 → Dec 2026 expected | cardiomyopathy, heart failure | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06162715 | Oct 2024 → Jan 2027 expected | morbid obesity | Vanderbilt University Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 342 trials · 24 met primary | ||||||
| Phase 3 | NCT07829198 | Jan 2027 → Dec 2028 expected | obesity disorder | University of Porto | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07817875 | Sep 2026 → Dec 2029 expected | obesity disorder | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07671248 | Aug 2026 → Jul 2028 expected | cannabis dependence | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07635953 | Jul 2026 → Jul 2029 expected | diabetes mellitus | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07481747 | Feb 2026 → Feb 2027 expected | obesity disorder | Hudson Biotech | Recruiting | No outcome recorded |
| Phase 3 | NCT07165028 | Oct 2025 → Aug 2030 expected | metabolic dysfunction-associated steatotic liver disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06937099 | Jun 2025 → May 2028 expected | Crohn disease, obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06937086 | Jun 2025 → Apr 2028 expected | obesity disorder, ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06962280 | May 2025 → Nov 2026 expected | obesity disorder, type 1 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06914895 | Apr 2025 → Nov 2026 expected | obesity disorder, type 1 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06630585 | Feb 2025 → Jun 2026 overdue | type 1 diabetes mellitus | University of Bern | Recruiting | No outcome recorded |
| Phase 3 | NCT06918405 | Jan 2025 → Jun 2026 overdue | obesity disorder | Chittagong Medical College | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06246799 | Nov 2024 → Apr 2029 expected | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 3 | NCT06534411 | Nov 2024 → Jun 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06588283 | Sep 2024 → Jan 2026 | obesity disorder, psoriasis | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT06588296 | Sep 2024 → Nov 2025 | obesity disorder, psoriatic arthritis | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT06439277 | Jun 2024 → Oct 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06075667 | Oct 2023 → Jun 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06047548 | Sep 2023 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05963022 | Aug 2023 → Oct 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05822830 | Apr 2023 → Nov 2024 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05691712 | Feb 2023 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05556512 | Oct 2022 → Oct 2027 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05412004 | Jun 2022 → Mar 2024 | obesity disorder, obstructive sleep apnea syndrome | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05260021 | Apr 2022 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05024032 | Sep 2021 → Dec 2022 | metabolic disease, obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04844918 | May 2021 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04847557 | Apr 2021 → Jul 2024 | diastolic heart failure, obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04660643 | Mar 2021 → Apr 2023 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04657016 | Mar 2021 → Apr 2023 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04657003 | Mar 2021 → Mar 2023 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04537923 | Oct 2020 → Oct 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04255433 | May 2020 → Jun 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04093752 | Dec 2019 → Nov 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04184622 | Dec 2019 → Apr 2022 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT04039503 | Aug 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT03987919 | Jul 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT03954834 | Jun 2019 → Oct 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT03861052 | May 2019 → Mar 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT03882970 | Apr 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT03861039 | Mar 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03730662 | Nov 2018 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 431 trials · 2 met primary | ||||||
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07630454 | Aug 2026 → Aug 2029 expected | atrial fibrillation, diastolic heart failure | Yunlong Wang | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07588438 | Jul 2026 → Aug 2027 expected | obesity disorder, type 2 diabetes mellitus | Las Rías Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07706088 | Jul 2026 → Jul 2028 expected | diabetes mellitus, neuropathy, small fiber | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07707778 | Jun 2026 → Dec 2027 expected | HIV infectious disease, diabetes mellitus, hyperlipidemia, metabolic dysfunction-associated steatotic liver disease +2 | National Taiwan University Clinical Trial Center | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07257484 | Jun 2026 → Dec 2027 expected | breast cancer, obesity disorder | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 4 | NCT07554638 | Jun 2026 → Apr 2029 expected | diastolic heart failure, obesity disorder | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07218445 | Apr 2026 → Sep 2027 expected | obesity disorder, premature menopause | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07483801 | Mar 2026 → Apr 2027 expected | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07438444 | Feb 2026 → Oct 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT07423247 | Jan → Jul 2026 overdue | — | Shahid Beheshti University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07247084 | Nov 2025 → Jul 2029 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT07154719 | Oct 2025 → Feb 2027 expected | obesity disorder, osteoporosis | Pennington Biomedical Research Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06801015 | Oct 2025 → Jan 2028 expected | obesity disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07096908 | Jul 2025 → Feb 2028 expected | obesity disorder, type 1 diabetes mellitus | Dasman Diabetes Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06861439 | Jul 2025 → Oct 2027 expected | obesity disorder | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07057310 | May 2025 → Dec 2026 expected | obesity disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06721507 | Mar 2025 → Dec 2026 expected | obesity disorder | Marlene Starr | Recruiting | No outcome recorded |
| Phase 4 | NCT06857942 | Mar 2025 → May 2028 expected | obesity disorder, psoriasis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 4 | NCT06864026 | Mar 2025 → Aug 2027 expected | obesity disorder, psoriatic arthritis | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06774079 | Mar 2025 → Mar 2027 expected | Crohn disease | University of Miami | Recruiting | No outcome recorded |
| Phase 4 | NCT06854614 | Mar 2025 → Apr 2027 expected | obesity disorder | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06657209 | Jan 2025 → Dec 2027 expected | prediabetes syndrome, type 2 diabetes mellitus | Stanford University | Recruiting | No outcome recorded |
| Phase 4 | NCT06191848 | Nov 2024 → May 2027 expected | obesity disorder, osteoarthritis, knee | University of Melbourne | Recruiting | No outcome recorded |
| Phase 4 | NCT06635057 | Oct 2024 → Apr 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT06606821 | Oct 2024 → Mar 2027 expected | atherosclerotic cardiovascular disease, coronary artery disorder, coronary microvascular disorder, obesity disorder | Tina Vilsbøll | Recruiting | No outcome recorded |
| Phase 4 | NCT06009653 | Sep 2023 → May 2024 | metabolic disease, obesity disorder | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 4 | NCT05706506 | Mar → Oct 2023 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT05564039 | Nov 2022 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 4 | NCT05433584 | Aug 2022 → Oct 2025 overdue | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | Met primary |
| Phase 4 | NCT05553093 | Mar 2022 → Dec 2023 overdue | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07811895 | Sep 2026 → Dec 2029 expected | obesity disorder | RenJi Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07866183 | Jun 2026 → Jun 2027 expected | — | National Medical Research Center for Therapy and Preventive Medicine | Recruiting | No outcome recorded |
| — | NCT07633639 | May 2026 → May 2028 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07176663 | Feb → Apr 2026 overdue | obesity disorder | Shahid Beheshti University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07373834 | Jan → Dec 2026 expected | obesity disorder | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT07364175 | Jan 2026 → Jan 2027 expected | hypertensive disorder, obesity disorder | Cambridge University Hospitals NHS Foundation Trust | Recruiting | No outcome recorded |
| — | NCT07319975 | Dec 2025 → Oct 2026 expected | obesity disorder | Istanbul Galata University | Not yet recruiting | No outcome recorded |
| — | NCT07293325 | Jun 2025 → Apr 2027 expected | obesity disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT07303556 | Dec 2024 → Jul 2025 overdue | heart failure, hypertensive disorder, type 2 diabetes mellitus | Nazarbayev University | Active not recruiting | No outcome recorded |
| — | NCT07368855 | May 2024 → Jul 2025 | depressive disorder, obesity disorder | University of California, San Diego | Completed | No outcome recorded |
| — | NCT06301256 | Mar 2024 → Mar 2025 | hidradenitis suppurativa | Florida Academic Centers Research and Education, LLC | Unknown | No outcome recorded |
| Comparator or background therapy50 trials | ||||||
| Phase 1 | NCT07842640 Comparator | Aug 2026 → Jun 2027 expected | — | Ascletis Pharma Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT07559500 Comparator | May 2026 → Dec 2031 expected | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 1 | NCT06345066 Background | Apr 2024 → Sep 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05822544 Background | Apr 2023 → Feb 2026 overdue | obesity disorder, type 2 diabetes mellitus | OrsoBio, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT05582096 Background | Nov 2022 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT07245771 Background | Nov 2025 → Feb 2027 expected | obesity disorder | Ikaria Bioscience Pty Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07000955 Comparator | Jun 2025 → Sep 2026 overdue | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06700538 Background | Dec 2024 → Sep 2027 expected | obesity disorder | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07796477 Comparator | Nov 2026 → Sep 2027 expected | type 2 diabetes mellitus | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06732245 Comparator | Aug 2026 → Aug 2027 expected | obesity disorder | Biomed Industries, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07676331 Comparator | Aug 2026 → Mar 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | Universitaire Ziekenhuizen KU Leuven | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07671391 Background | Aug 2026 → Jul 2027 expected | — | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07573163 Comparator | Jul 2026 → Jul 2028 expected | ACTH-independent Cushing syndrome | Alaa Sada | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07046819 Comparator | Jun → Jul 2026 overdue | alcohol-related disorders, metabolic dysfunction and alcohol associated liver disease | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 2 | NCT07521631 Comparator | Mar 2026 → Feb 2027 expected | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07220473 Comparator | Feb 2026 → Nov 2027 expected | — | The University of Texas Medical Branch, Galveston | Recruiting | No outcome recorded |
| Phase 2 | NCT07128082 Comparator | Oct 2025 → Dec 2026 expected | long COVID-19 | Scripps Translational Science Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06965413 Background | May 2025 → Sep 2026 overdue | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06911203 Comparator | Apr 2025 → Jan 2026 overdue | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06737042 Comparator | Feb 2025 → Feb 2026 | obesity disorder | Gan and Lee Pharmaceuticals, USA | Completed | Met primary |
| Phase 2 | NCT06565611 Comparator | Aug 2024 → Feb 2025 overdue | obesity disorder | Palatin Technologies, Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06445075 Background | May 2024 → Mar 2025 | — | Scholar Rock, Inc. | Completed | Met primary |
| Phase 2 | NCT06326047 Comparator | Mar 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06326060 Comparator | Mar 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT07845500 Comparator | Oct 2026 → Feb 2028 expected | obesity disorder | Pfizer | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07298915 Background | Aug → Dec 2026 expected | obesity disorder | University of Virginia | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07834398 Comparator | Nov 2025 → Apr 2026 | obesity disorder | Zagazig University | Completed | No outcome recorded |
| Phase 3 | NCT07820111 Comparator | Oct 2025 → Mar 2026 | — | Zagazig University | Completed | No outcome recorded |
| Phase 3 | NCT06662383 Comparator | Nov 2024 → Nov 2026 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06221969 Comparator | Jan 2024 → Mar 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06131437 Comparator | Nov 2023 → Dec 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT07832084 Comparator | Nov 2026 → Apr 2027 expected | obesity disorder | Jing Luo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07777575 Background | Sep 2026 → May 2027 expected | obesity disorder | Technical University of Munich | Recruiting | No outcome recorded |
| Phase 4 | NCT07191873 Comparator | Aug 2026 → Aug 2027 expected | pseudotumor cerebri | Duke University | Recruiting | No outcome recorded |
| Phase 4 | NCT07697391 Comparator | Jul 2026 → Oct 2027 expected | obesity disorder, type 2 diabetes mellitus | The First Affiliated Hospital of Anhui Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07555730 Comparator | Apr 2026 → Sep 2028 expected | type 2 diabetes mellitus | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07354880 Comparator | Jan 2026 → Jun 2027 expected | congenital heart disease, obesity disorder | University Medical Centre Ljubljana | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07058155 Comparator | Dec 2025 → Feb 2029 expected | cirrhosis of liver, morbid obesity, portal hypertension | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07326111 Comparator | Dec 2025 → Dec 2028 expected | obesity disorder, polycystic ovary syndrome | University of Bonn | Recruiting | No outcome recorded |
| Phase 4 | NCT06901245 Comparator | May 2025 → Jun 2026 overdue | Prader-Willi syndrome, acquired hypothalamic obesity | Grace Kim | Recruiting | No outcome recorded |
| Phase 4 | NCT06803888 Comparator | Jan 2025 → Jul 2027 expected | obesity disorder | Ali Aminian | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06533527 Comparator | Jul 2024 → May 2025 | gastroparesis, obesity disorder, type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT06374875 Comparator | Jul 2024 → May 2029 expected | NAFLD1, fibrotic liver disease, metabolic dysfunction-associated steatohepatitis, obesity disorder | Ali Aminian | Recruiting | No outcome recorded |
| Phase 4 | NCT05708859 Comparator | Jan 2024 → Dec 2025 overdue | atherosclerosis, type 2 diabetes mellitus | Matthew J. Budoff | Recruiting | No outcome recorded |
| Phase 4 | NCT05812183 Background | Jul 2023 → Feb 2025 | — | University of California, Los Angeles | Withdrawn | No outcome recorded |
| — | NCT07382024 Comparator | Jun 2026 → Dec 2027 expected | obesity disorder, persistent atrial fibrillation | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07574723 Comparator | May 2026 → May 2029 expected | obesity disorder | Dasman Diabetes Institute | Recruiting | No outcome recorded |
| — | NCT07589322 Comparator | Mar 2026 → Sep 2028 expected | abdominal obesity-metabolic syndrome | Tri-Service General Hospital (TSGH) | Recruiting | No outcome recorded |
| — | NCT07443956 Comparator | Mar 2026 → Feb 2028 expected | obesity disorder, psoriatic arthritis | NHS Greater Glasgow and Clyde | Recruiting | No outcome recorded |
| — | NCT05990374 Comparator | Aug 2023 → Jan 2024 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 78
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Eli Lilly and Company | Results New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity lilly.com ↗
These data showed that when Taltz and Zepbound were used together, changes were observed in more psoriasis disease-associated and metabolic biomarkers compared to Taltz monotherapy. |
| 2026-09-30 | Eli Lilly and Company | Results Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes lilly.com ↗
At 48 weeks, all combinations of EloraTZP met the primary and secondary endpoints, delivering substantial weight loss and A1C reduction. |
| 2026-09-29 | Novo Nordisk A/S | Results Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis novonordisk.com ↗
Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis |
| 2026-09-29 | Novonordisk Us | Results Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD novonordisk-us.com ↗
These findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. |
| 2026-09-29 | Eli Lilly and Company | Results Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison lilly.com ↗
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity |
| 2026-09-21 | Novo Nordisk A/S | Results Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial novonordisk.com ↗
In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1%, respectively. |
| 2026-09-15 | Eli Lilly and Company | Results Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health lilly.com ↗
SURPASS-EARLY Pre-Specified Analysis: Mounjaro improved markers of beta cell function and insulin sensitivity in early type 2 diabetes. |
| 2026-08-31 | Eli Lilly and Company | Results New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity lilly.com ↗
New data show these improvements were maintained or further improved through Week 52, with no new safety concerns identified. |
| 2026-08-28 | Eli Lilly and Company | Regulatory La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 lilly.com ↗ |
| 2026-08-28 | Eli Lilly and Company | Regulatory FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes lilly.com ↗ |
| 2026-08-26 | Eli Lilly and Company | Results Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study lilly.com ↗
Individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits |
| 2026-08-25 | Caliway Biopharmaceuticals Co., Ltd. | Regulatory 雙喜臨門！康霈生技CBL-514合併療法獲美國FDA核准進入二期臨床，大範圍局部減脂樞紐三期試驗 SUPREME-01 已啟動收案 caliwaybiopharma.com ↗ |
| 2026-07-27 | Caliway Biopharmaceuticals Co., Ltd. | Regulatory 鎖定 GLP-1類減重藥物復胖痛點！康霈 CBL-514 合併療法向美國 FDA 提出二期臨床試驗申請；減少內臟脂肪臨床數據獲歐洲糖尿病研究協會 EASD 2026 年會口頭發表 caliwaybiopharma.com ↗
CBL-514 合併禮來 Zepbound® (tirzepatide) 之多中心二期臨床試驗 CBL-0201WR已正式向美國 FDA 提出新藥臨床試驗 (IND) 申請。 |
| 2026-07-08 | Impax Laboratories, LLC | Regulatory Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector amneal.com ↗
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) and Adalvo announced that the U.S. Food and Drug Administration (FDA) has accepted for review two Abbreviated New Drug Applications (ANDAs) filed at NCE-1 for generic tirzepatide injection in the United States. |
| 2026-06-29 | Sandoz | Regulatory US FDA accepts Sandoz applications for proposed in-house development of generic tirzepatide GLP-1s sandoz.com ↗ |
| 2026-06-17 | Lexaria Bioscience Corp. | Results GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand lexariabioscience.com ↗
The following table summarizes the dramatic improvements in GI AEs that Lexaria has realized when testing three (semaglutide, tirzepatide, and liraglutide) of the major GLP-1 drugs on the market today with its DehydraTECH™ technology in an oral format: |
| 2026-06-06 | Novo Nordisk A/S | Results People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data novonordisk.com ↗
This retrospective claims analysis, across >64,000 US adults, offered exploratory insights of patients with type 2 diabetes who were escalated from 1 mg to 2 mg semaglutide vs switching to tirzepatide, in a real-world dose titration1 |
| 2026-06-05 | OrsoBio, Inc | Results OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions orsobio.com ↗
The randomized, double-blind, placebo-controlled study demonstrated significant improvements in weight loss, insulin sensitivity, liver health, and body composition compared with tirzepatide monotherapy. |
| 2026-05-28 | Eli Lilly and Company | Results Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care lilly.com ↗
SURPASS-CVOT: Mounjaro and dulaglutide demonstrated improvements in quality of life and daily functioning over the course of multiple years of treatment. |
| 2026-05-27 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 arrowheadpharma.com ↗
ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in individuals with obesity with or without Type 2 Diabetes Mellitus (T2DM) |
| 2026-05-12 | Eli Lilly and Company | Results Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials lilly.com ↗ |
| 2026-03-28 | Eli Lilly and Company | Results Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity lilly.com ↗
At the primary endpoint of 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz monotherapy. |
| 2026-02-23 | Novo Nordisk A/S | Results Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved novonordisk.com ↗
The trial did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to tirzepatide after 84 weeks. |
| 2026-02-23 | Eli Lilly and Company | Regulatory Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. |
| 2026-02-18 | Eli Lilly and Company | Results Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight lilly.com ↗
At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superior skin clearance and weight loss versus Taltz monotherapy. |
| 2026-01-23 | Caliway Biopharmaceuticals Co., Ltd. | Regulatory 康霈就 CBL-0201WR Phase 2 IND 申請進度之說明 caliwaybiopharma.com ↗
本公司經FDA 通知於今日完成會議溝通，考量CBL-514 臨床單用並無顯著體重下降的「減重」效果，因而建議本公司就本次試驗擬定之「體重管理」適應症進行調整。 |
| 2026-01-08 | Eli Lilly and Company | Results Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight lilly.com ↗
At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for superiority to Taltz monotherapy. |
| 2026-01-06 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition arrowheadpharma.com ↗
ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide alone |
| 2025-12-30 | Lexaria Bioscience Corp. | Results Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 lexariabioscience.com ↗
In the DHT-tirzepatide arm, plasma tirzepatide concentrations were quantifiable only through week 12, with the maximum plasma concentrations observed at week 8. |
| 2025-12-23 | Lexaria Bioscience Corp. | Results Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 lexariabioscience.com ↗
Each of the DHT arms had lower rates of overall treatment emergent adverse events (“ AEs “) and gastrointestinal (“ GI “) AEs compared to the Rybelsus ® control arm: |
| 2025-12-16 | OrsoBio, Inc | Results OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide orsobio.com ↗
At week 24, participants receiving TLC-6740 plus tirzepatide achieved mean weight loss of 13.3%, compared with 8.8% with tirzepatide alone. |
| 2025-09-17 | Eli Lilly and Company | Results Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes lilly.com ↗
At 30 weeks, Mounjaro met the primary and all key secondary endpoints, achieving superior improvements in A1C and body mass index (BMI) compared to placebo. |
| 2025-07-31 | Eli Lilly and Company | Results Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease lilly.com ↗
In addition, while not controlled for multiplicity-adjusted type-1 error, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality. |
| 2025-07-28 | Lexaria Bioscience Corp. | Results Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study lexariabioscience.com ↗
After 8 weeks of treatment, Lexaria’s DehydraTECH-GLP-1 arms are tracking very nicely from a safety and tolerability perspective relative to the Rybelsus® control arm; most notably in terms of reductions in the incidence of gastrointestinal (“ GI “) adverse events (“ AEs “): |
| 2025-06-21 | BioAge Labs, Inc. | Results BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions bioagelabs.com ↗
An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide |
| 2025-06-18 | Scholar Rock, Inc. | Results Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss scholarrock.com ↗
Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tirzepatide alone, leading to higher quality weight loss. |
| 2025-05-29 | Eli Lilly and Company | Results Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions lilly.com ↗
Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1) |
| 2025-05-11 | Eli Lilly and Company | Results Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine lilly.com ↗
For the primary endpoint, participants treated with Zepbound achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy at 72 weeks using the treatment-regimen estimand,1 a 47% greater relative weight loss. |
| 2025-04-17 | Palatin Technologies, Inc | Results Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide palatin.com ↗
Using a validated daily appetite questionnaire, the study showed that patients receiving co-administered bremelanotide + tirzepatide, tirzepatide alone, and bremelanotide alone, experienced significant improvements in appetite suppression, fullness, and satiety. |
| 2025-03-31 | Palatin Technologies, Inc | Results Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study palatin.com ↗
Primary endpoint met in the 8-week treatment study (highly statistically significant). |
| 2025-03-19 | Tanabe Pharma Corporation | Regulatory Announcement of NHI Price Listing and Release Date of “Zepbound®”, a Long-Acting GIP/GLP-1 Receptor Agonist, for the Chronic Disease of “Obesity Disease” with Multiple Factors tanabe-pharma.com ↗
was listed in the National Health Insurance (NHI) price list with the indication “obesity disease*” today on March 19, 2025 and will be released in Japan on April 11, 2025. |
| 2025-03-18 | Lexaria Bioscience Corp. | Results Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound® lexariabioscience.com ↗
The results were unexpectedly positive, showing that orally delivered DehydraTECH-tirzepatide reached roughly equal end of Study blood-concentration levels as the injected drug. |
| 2025-01-14 | Lexaria Bioscience Corp. | Results Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound® lexariabioscience.com ↗
The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47% . |
| 2025-01-08 | Scholar Rock, Inc. | Results Scholar Rock Highlights 2025 Strategic Priorities scholarrock.com ↗
Scholar Rock disclosed new preclinical data which showed that SRK-439 protected against tirzepatide-induced muscle loss in DIO mice. |
| 2024-12-27 | Tanabe Pharma Corporation | Regulatory "Zepbound®", a Long-Acting GIP/GLP-1 Receptor Agonist, Approved for the Chronic Disease of "Obesity Disease" with Multiple Factors tanabe-pharma.com ↗ |
| 2024-12-20 | Eli Lilly and Company | Regulatory FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. |
| 2024-12-04 | Eli Lilly and Company | Results Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. |
| 2024-11-16 | Eli Lilly and Company | Results Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity lilly.com ↗
Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. |
| 2024-11-13 | Eli Lilly and Company | Results Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks lilly.com ↗
Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide. |
| 2024-11-04 | BioAge Labs, Inc. | Results BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 bioagelabs.com ↗
Our two presentations provide evidence supporting the ability of BioAge’s azelaprag to enhance weight loss when combined with oral appetite suppression mechanisms, and to protect against excess weight gain and provide metabolic benefits as a monotherapy. |
| 2024-08-20 | Eli Lilly and Company | Results Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight lilly.com ↗
Weekly tirzepatide injections (5 mgi, 10 mg, 15 mg) significantly reduced the risk of progression to type 2 diabetes by 94% ii among adults with pre-diabetes and obesity or overweight compared to placebo. |
| 2024-08-01 | Eli Lilly and Company | Results Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity lilly.com ↗
Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo |
| 2024-06-21 | Eli Lilly and Company | Results Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution lilly.com ↗
In a key secondary endpoint, the efficacy estimand showed that 43.0% (Study 1) and 51.5% (Study 2) of participants treated with tirzepatide at the highest dose met the criteria for disease resolution. |
| 2024-06-08 | Eli Lilly and Company | Results Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks lilly.com ↗ |
| 2024-05-08 | Tanabe Pharma Corporation | Regulatory Announcement of Approval Submission and Marketing Alliance in Japan for Tirzepatide as a Drug for Obesity Disease tanabe-pharma.com ↗
Announcement of Approval Submission and Marketing Alliance in Japan for Tirzepatide as a Drug for Obesity Disease |
| 2024-04-17 | Eli Lilly and Company | Results Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. |
| 2023-12-11 | Eli Lilly and Company | Results Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks lilly.com ↗
Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints for both estimandsi,ii, compared to placebo 52 weeks after randomization. |
| 2023-11-08 | Eli Lilly and Company | Regulatory FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems lilly.com ↗
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. |
| 2023-10-15 | Eli Lilly and Company | Results Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks lilly.com ↗ |
| 2023-07-27 | Eli Lilly and Company | Results Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies lilly.com ↗
Eli Lilly and Company (NYSE: LLY) announced results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. |
| 2023-06-24 | Eli Lilly and Company | Results Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes lilly.com ↗
For the efficacy estimand, 81.6% (10 mg) and 86.4% (15 mg) of people taking tirzepatide achieved at least 5% body weight reduction, compared to 30.5% of those taking placebo. |
| 2023-04-27 | Eli Lilly and Company | Results Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 lilly.com ↗
Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2. |
| 2022-10-06 | Eli Lilly and Company | Regulatory Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities lilly.com ↗
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. |
| 2022-06-06 | Eli Lilly and Company | Results New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® lilly.com ↗
Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study |
| 2022-06-04 | Eli Lilly and Company | Results Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight lilly.com ↗
Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimandsi. |
| 2022-05-13 | Eli Lilly and Company | Regulatory FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes lilly.com ↗ |
| 2022-04-28 | Eli Lilly and Company | Results Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 lilly.com ↗
In a key secondary endpoint, 55% (10 mg) and 63% (15 mg) of people taking tirzepatide achieved at least 20% body weight reductions compared to 1.3% of those taking placebo. |
| 2021-10-19 | Eli Lilly and Company | Results Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk lilly.com ↗
In newly published data from the treatment period after 52 weeks, participants taking tirzepatide maintained A1C and weight control for up to two years. |
| 2021-09-30 | Eli Lilly and Company | Results Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study lilly.com ↗
In an exploratory endpoint of this CGM sub-study, participants taking tirzepatide 15 mg experienced 91.2% time in range (71-180 mg/dL) at 52 weeks. |
| 2021-09-30 | Eli Lilly and Company | Results Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study lilly.com ↗
The MRI (magnetic resonance imaging) sub-study achieved its primary and secondary endpoints. |
| 2021-06-26 | Eli Lilly and Company | Results Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes lilly.com ↗
In the SURPASS-1 results, tirzepatide led to significant improvements across all primary and key secondary endpoints with clinically meaningful A1C reductions and robust weight loss among study participants, who had a relatively short duration of type 2 diabetes. |
| 2021-06-25 | Eli Lilly and Company | Results Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes lilly.com ↗
These results, which will also be featured during an ADA-sponsored symposium on Tuesday, June 29, showed that all three tirzepatide doses achieved greater A1C and weight reductions compared to semaglutide. |
| 2021-05-20 | Eli Lilly and Company | Results Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial lilly.com ↗
All three doses of tirzepatide (5 mg, 10 mg and 15 mg) led to superior A1C and body weight reductions compared to insulin glargine for both estimandsii. |
| 2021-03-04 | Eli Lilly and Company | Results Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes lilly.com ↗
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) 40-week SURPASS-2 clinical trial. |
| 2021-02-17 | Eli Lilly and Company | Results Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program lilly.com ↗
Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) SURPASS-3 and SURPASS-5 phase 3 clinical trials after 52 weeks and 40 weeks, respectively. |
| 2020-12-09 | Eli Lilly and Company | Results Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes lilly.com ↗ |
| 2019-06-08 | Eli Lilly and Company | Results Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions® lilly.com ↗
Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes. |
| 2018-10-04 | Eli Lilly and Company | Results Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes lilly.com ↗
Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes. |
All press releases naming this drug 113 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 113 releases opens the full record — a long page | ||
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 223 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tirzepatide | “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗218“Tirzepatide (Mounjaro), a drug developed for the treatment of type 2 diabetes, is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 that has been...” NCT07354880 ↗ “Participants will receive 16-week tirzepatide pretreatment prior to FET alongside lifestyle modification guidance, with a target weight loss of 10%-15% of total body weight.” NCT07811895 ↗ “Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group.” NCT06374875 ↗ “Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?” NCT07368855 ↗ “Participants on tirzepatide at baseline will gradually reduce their dose from 15mg to 12.5mg to 10mg to 7.5mg to 5mg once a week to 5mg every other week.” NCT07832084 ↗ “Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine.” NCT07058155 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery.” NCT06734273 ↗ “Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.” NCT06326047 ↗ “Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide” NCT07223242 ↗ |
| Known as | BG-121 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Known as | LIPOLESS | “Participants will receive subcutaneous injections of tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) once weekly.” NCT07588438 ↗ |
| Known as | LY3298176 | “A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both” NCT05260021 ↗3“A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities” NCT06075667 ↗ “A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity” NCT06037252 ↗ “LY3298176” NCT04311411 ↗ |
| Known as | Mounjaro | “Tirzepatide (Mounjaro), a drug developed for the treatment of type 2 diabetes, is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 that has been...” NCT07354880 ↗5“We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue,...” NCT06745128 ↗ “If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗ “New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health.” NCT07179120 ↗ “Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist • Other Names: * Mounjaro * Zepbound” NCT06732245 ↗ “Tirzepatide (Mounjaro)” NCT07303556 ↗ |
| Known as | Mounjaro (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Known as | Munjaro | “the effects of the anti-obesity drug tirzepatide (Munjaro) on cardiovascular and metabolic factors in obese patients with ACHD.” NCT07354880 ↗ |
| Known as | Spartina | “weekly injection of Tirzepatide (Spartina)” NCT07176663 ↗ |
| Known as | Tirzepatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Known as | Tirzetta | “30 participants will receive tirzepatide (Tirzetta)” NCT07866183 ↗ |
| Known as | TZP | “This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D).” NCT06820281 ↗ |
| Known as | Zepbound | “We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue,...” NCT06745128 ↗6“If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗ “injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication” NCT06774079 ↗ “The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID.” NCT07128082 ↗ “Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist • Other Names: * Mounjaro * Zepbound” NCT06732245 ↗ “Tirzepatide (Zepbound)” NCT05812183 ↗ |
| Known as | Zepbound (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297839 ↗ |
| Action | Activate | “Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist” PMID 35210595 ↗ Feb 20222“Gastric inhibitory polypeptide receptor agonist” CHEMBL4297839 ↗ “Glucagon-like peptide 1 receptor agonist” CHEMBL4297839 ↗ |
| Modality | Peptide | “Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes.” PMID 37786396 ↗ Nov 2023 |
| Route | Subcutaneous | “Administered SC” NCT03131687 ↗ |
| Target | GIPR | “Gastric inhibitory polypeptide receptor agonist” CHEMBL4297839 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL4297839 ↗ |